CLOs on the Move

DermTech

www.dermtech.com

 
Welcome to the new era of skin cancer detection. At DermTech we bring precision to the practice of dermatology through non-invasive genomic testing. And we developed the Smart Sticker that`s making it possible. The DermTech Smart Sticker collects an RNA sample by painlessly lifting skin cells off the entire surface of a mole. This gives doctors the power to diagnose skin cancer in its earliest stages—without a scalpel, without cutting, without scarring. After collection, stickers are sent to our team of scientists in the Gene Lab, the only commercial lab to extract nucleic acids and other proteins from non-invasive skin ...
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.dermtech.com
  • 11099 North Torrey Pines Road Suite 100
    La Jolla, CA USA 92037
  • Phone: 858.450.4222

Executives

Name Title Contact Details
Jennifer Eilemberg
Chief Compliance Officer Profile
Ray Akhavan
General Counsel Profile

Similar Companies

RTD Company

RTD Company is a Andover, MN-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

Spinemark

Spinemark is a San Diego, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Cryofab

Cryofab is a Kenilworth, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Genome Quebec

Genome Quebec is a Montreal, QC-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

Yumanity

Yumanity Therapeutics is transforming drug discovery for neurodegenerative diseases caused by protein misfolding. Despite the fact that an estimated 50 million people worldwide suffer from diseases affecting the brain and central nervous system, there are no approved disease-modifying therapies or cures. Yumanity is working to identify and develop new, disease-modifying therapies that address several illnesses with critical unmet medical needs, including Alzheimer`s disease, Parkinson`s disease and amyotrophic lateral sclerosis (ALS). The company`s approach concentrates on correcting the cellular pathologies driven by misfolded proteins, the altered biology or phenotypes driving these diseases. Yumanity Therapeutics was founded in December 2014 by Susan Lindquist, Ph.D., award-winning protein folding expert, and Tony Coles, M.D., a renowned biotech industry leader. The company`s proprietary platforms have already identified one potential new target for treating Parkinson`s disease, and Yumanity is actively advancing its new chemical lead series for this condition, as well as identifying additional compounds for Alzheimer`s disease and ALS. Targeting the underlying protein pathology of neurodegenerative diseases allows the company to discover therapies that may modify the root cause of these rather than only addressing their symptoms.